COMP <GO>
ALDX vs GRCE // DIVIDEND YIELD & FCF PAYOUT SAFETY
Aldeyra Therapeutics Inc. (NASDAQ) VS. Grace Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ALDX 1
— GRCE 3
■ METRIC PARITY
LAST: $0.66 (-3.58%) • MKT CAP: $39.8M
dividend-safety
0.00%
LAST: $1.94 (-3.48%) • MKT CAP: $40.8M
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ALDX VS. GRCE)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ALDX | GRCE | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -18.90% | -16.10 | GRCE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -21.73% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 2/9 | +2.00 | ALDX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 24.4 | 46.2 | -21.71 | GRCE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $39.8M | $40.8M | -$1.0M | GRCE | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ALDX REV | GRCE REV | ALDX GROSS % | GRCE GROSS % | ALDX FCF | GRCE FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$33.3M | -$8.9M |
| FY 2024 | $0 | $0 | — | — | -$43.2M | -$14.9M |
| FY 2023 | $0 | $0 | — | — | -$30.3M | -$12.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ALDX // BETA —
GRCE // BETA —